The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with ...

The biologic DMARDs rituximab and abatacept were associated with an increased risk for incident cancers in patients with RA ...

"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

Despite treatment advancements with the introduction of HDMTX and rituximab, up to half of patients will have disease relapse, and 10%–15% may have primary refractory disease.

With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...

Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib in adult patients ...